Is Genomic Health (NASDAQ:GHDX) a Stock One Should Sell Following Today’s Ladenburg Downgrade?

June 13, 2018 - By Henry Gaston

Genomic Health, Inc. (NASDAQ:GHDX) Logo

Investors sentiment increased to 1.42 in Q1 2018. Its up 0.29, from 1.13 in 2017Q4. It increased, as 16 investors sold Genomic Health, Inc. shares while 29 reduced holdings. 24 funds opened positions while 40 raised stakes. 31.06 million shares or 0.50% less from 31.21 million shares in 2017Q4 were reported.

Massachusetts Financial Services Ma reported 14,447 shares or 0% of all its holdings. Plante Moran Advsrs Ltd Liability holds 0% or 200 shares. Ameriprise Incorporated holds 0.02% or 1.51M shares in its portfolio. Federated Invsts Pa has 0% invested in Genomic Health, Inc. (NASDAQ:GHDX) for 1,388 shares. Schwab Charles accumulated 0.01% or 430,626 shares. Citigroup Inc holds 0% of its portfolio in Genomic Health, Inc. (NASDAQ:GHDX) for 8,921 shares. Los Angeles Capital Management Equity Research, a California-based fund reported 50,921 shares. Gsa Ptnrs Ltd Liability Partnership owns 44,300 shares or 0.07% of their US portfolio. Aqr Lc owns 0.01% invested in Genomic Health, Inc. (NASDAQ:GHDX) for 148,223 shares. Metropolitan Life New York has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). State Street has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). Sei Invs Co owns 678 shares. Parametric Associate Ltd Liability Co has 0% invested in Genomic Health, Inc. (NASDAQ:GHDX) for 15,946 shares. University Of Notre Dame Du Lac stated it has 80,903 shares. The New York-based Jpmorgan Chase & has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX).

Since December 14, 2017, it had 0 buys, and 15 sales for $7.32 million activity. Shares for $177,566 were sold by Cole G Bradley on Tuesday, January 9. $329,336 worth of Genomic Health, Inc. (NASDAQ:GHDX) was sold by Popovits Kimberly J on Wednesday, February 14. 5,334 shares were sold by Febbo Phillip G., worth $197,298 on Tuesday, December 19. Another trade for 5,500 shares valued at $201,543 was sold by Shak Steven. 21,000 shares were sold by Leber Laura, worth $699,000.

Genomic Health (NASDAQ:GHDX) Receives a Downgrade

This morning Genomic Health (NASDAQ:GHDX) has been downgraded by Ladenburg to a “Hold” rating in analysts note released on Wednesday morning. The firm after the upgrade has a $49.5000 target price per share shares.

Genomic Health, Inc. (NASDAQ:GHDX) Ratings Coverage

Among 6 analysts covering Genomic Health (NASDAQ:GHDX), 1 have Buy rating, 1 Sell and 4 Hold. Therefore 17% are positive. Genomic Health has $4500 highest and $28.0 lowest target. $35’s average target is -30.14% below currents $50.1 stock price. Genomic Health had 8 analyst reports since December 14, 2017 according to SRatingsIntel. As per Friday, March 9, the company rating was maintained by Canaccord Genuity. The stock has “Buy” rating by Canaccord Genuity on Tuesday, January 16. Canaccord Genuity maintained Genomic Health, Inc. (NASDAQ:GHDX) on Monday, June 4 with “Buy” rating. As per Thursday, May 3, the company rating was maintained by Deutsche Bank. The company was downgraded on Wednesday, December 20 by William Blair. The company was maintained on Thursday, March 8 by Piper Jaffray.

The stock decreased 1.18% or $0.6 during the last trading session, reaching $50.1. About 257,390 shares traded or 27.12% up from the average. Genomic Health, Inc. (NASDAQ:GHDX) has risen 30.62% since June 14, 2017 and is uptrending. It has outperformed by 18.05% the S&P500.

Analysts await Genomic Health, Inc. (NASDAQ:GHDX) to report earnings on August, 7. They expect $0.07 EPS, up 187.50 % or $0.15 from last year’s $-0.08 per share. GHDX’s profit will be $2.48M for 178.93 P/E if the $0.07 EPS becomes a reality. After $0.13 actual EPS reported by Genomic Health, Inc. for the previous quarter, Wall Street now forecasts -46.15 % negative EPS growth.

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company has market cap of $1.77 billion. It develops and commercializes genomic clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. It currently has negative earnings. The firm offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit.

More recent Genomic Health, Inc. (NASDAQ:GHDX) news were published by: which released: “Top Analyst Upgrades and Downgrades: Applied Materials, Comcast, HUYA, Sprint, Time Warner, Yelp and More” on June 13, 2018. Also published the news titled: “Here’s Why Genomic Health Rocketed Higher Today” on June 04, 2018.‘s news article titled: “Pre-Open Movers 06/04: (VSAR) (VYGR) (GHDX) Higher; (NKTR) (JNCE) (CFX) Lower (more…)” with publication date: June 04, 2018 was also an interesting one.

Genomic Health, Inc. (NASDAQ:GHDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.